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Abstract
Introduction
Research Questions
Applicability to Clinical Practice
Current Understanding of PAH
 The Pulmonary Hypertension Association summarized the 
pathophysiologic pathways of PAH at its 2017 symposium:
Nitric oxide (NO): An endogenous pulmonary vasodilator; 
also possesses anti-proliferative properties. A relative 
deficiency of endothelial NO in the pulmonary vasculature 
may be one mechanism which contributes to the 
development of PAH.
Endogenous prostacyclins: Systemic and pulmonary 
vasodilators, anti-proliferative agents that also have 
antithrombotic/antiplatelet effects. Relative deficiency or 
down-regulation of endogenous prostacyclin may 
contribute to the development of PAH.
Endothelin-1: An endogenous vasoconstrictor.  Up-
regulation of endogenous endothelin-1 may also 
contribute to the pathogenesis of PAH. 
 The small vessel arteriopathy in PAH leads to a progressive 
rise in RV afterload and pulmonary vascular resistance 
(PVR). As a result, the RV undergoes remodeling changes, 
including right ventricular hypertrophy, dilatation and finally 
dysfunction. If PAH is left untreated, right ventricular failure 
will ultimately result in patients experiencing syncope, 
angina, edema and abdominal distention (Favilli et al., 
2015).  Right ventricular failure is the most common cause 
of death in patients with PAH (Sitbon and Morrell, 2012).
 BMPR2 epistatic effect on KCNK3 and TGF-Beta resulting 
in smooth muscle potassium and calcium channelopathy 
(Ma et al., 2013).
 PDLIM5 protein is produced in the smooth muscle cells of 
the pulmonary artery (Zhou, Chen and Raj, 2015).  Within 
the past year the American Lung Association has begun 
investigating the effect hypoxia has on the PDLIM5 
expression.  Of particular note is the suppressive effect 
PDLIM5 plays on the activation of a downstream protein 
SMAD2/3, which is responsible for cell signaling in smooth 
muscle (Ousterout et al., 2015).  This study is scheduled to 
conclude in 2019.
What is the correlation between genetic disorders like 
DMD and DS with increased incidence of PAH?
What has current and existing research shown in the 
understanding of pulmonary arterial hypertension?
What is the recommended, evidence based treatment 
modality for PAH specific to DMD and DS?
Among individuals with Duchenne muscular dystrophy and 
Down syndrome with co-morbid pulmonary arterial 
hypertension (PAH), has early recognition and treatment led 
to statistically significant increase in life expectancy versus 
previously undiagnosed or unrecognized PAH? 
Statement of the Problem
References
 Supportive therapy and general measures with expert 
referral upon suspicion.
 Advanced therapies initiated with confirmation through 
right heart catheterization and vasoreactivity testing.
 Treatment is centered around the individual’s 
limitation of physical activity.
 Individuals that demonstrated a vasoreactive 
response are treated with calcium channel 
blockers.
 Individuals that do not demonstrate a vasoreactive 
response:
 PH with slight limitation- Ambrisentan & tadalafil
 PH with marked limitation- Ambrisentan & 
tadalafil
 No improvement or deterioration- double or triple 
therapy
 Key to treating individuals with DMD or DS is the 
recognition of changes in behavior and activity by the 
provider
The genetic cause of significant disorders like Down 
syndrome (DS) and Duchenne muscular dystrophy 
(DMD) is well documented.  Pulmonary arterial 
hypertension (PAH), a co-morbid condition, is tied to 
mortality among these groups.    Individuals with the 
ability to communicate their symptoms and actively 
participate in treatment are at an advantage with 
subsequent benefit.  DS and DMD significantly decrease 
physical ability and communication capacity.  Genetic 
research has allowed for earlier identification of, or 
predisposition for, the development of PAH.  Work has 
also progressed toward manipulation at the genetic level 
to decrease the severity and even eradicate the 
cardiopulmonary disorder.  This information is beginning 
to be applied in treatment for individuals with PAH.  A 
literature review was conducted to identify the research, 
prediction methods and treatment of PAH in individuals 
with Duchenne muscular dystrophy (DMD) and Down 
syndrome (DS) as it relates to decreased mortality or 
increased life expectancy among those groups.  The 
results showed significant gains in the understanding of 
PAH, DS and DMD individually.  There was little evidence 
of research focusing on PAH as it pertains particularly to 
DS or DMD.
The 5th World Symposium on Pulmonary Hypertension,  
held in Nice, France, February 27 to March 1, 2013, 
identifies four specific types of PAH:  Idiopathic, 
Familial, Drug or Toxin Induced and Associated.  
Idiopathic PAH (IPAH) causes are unknown (Saji, 
2014).  Familial PAH (FPAH) has a genetic cause 
(Chew, Loyd & Austin, 2017).  Drug or Toxin Induced 
PAH is a growing concern (Peacock, Murphy, 
McMurray, Baballero & Stewart, 2007). The most 
common type of PAH, associated (APAH),  occurs 
along with other medical conditions (Chew et al., 2017)
Recent studies have provided insight in the diagnosis 
and screening for both familial and associated 
pulmonary arterial hypertension.  Research has led to 
earlier diagnosis of and screening for PAH (Tonelli et 
al., 2013). 
Unfortunately, co-morbid and/or exacerbating conditions 
often dictate patient outcome (Tonelli et al., 2013).  
Many disorders of the body cause APAH.  Two genetic 
conditions having co-morbid occurrence of APAH are 
Down syndrome and Duchenne muscular dystrophy.  
Both of these disorders have high mortality rates. 
Identifying the specific underlying pathophysiology and 
etiology of PAH when associated with DMD and DS is vitally 
important to treatment.  It is also important to understand 
that options with proven, evidence-based modalities 
particular to co-morbid conditions can have positive 
influence on patient outcomes, from increased life 
expectancy to improved quality of life.  Reviewing research 
which has been completed helps deepen the understanding 
of the direction future investigation in PAH is taking. 
Literature Review
Correlation between DMD or DS and incidence of PAH
DMD progresses with muscle wasting and connective 
tissue disorders.  These processes result in eventual 
dystrophy of the diaphragm and pneumonia.  A study 
comparing thirty-one individuals with DMD and eleven 
healthy individuals has shown a significant correlation (r = -
0.384, p = 0.0391) between plasma nitric oxide levels and 
ejection fraction measured by echocardiogram in the DMD 
group (Kasai et al., 2004).  The finding suggests that there 
is a significant decrease in production of nitric oxide as part 
of the disease process of DMD.  Decreased levels of nitric 
oxide have a direct effect on prostacyclin and a converse 
effect on endothelin.  A study of eight individuals with 
advanced development of DMD were evaluated by right 
heart catheterization.  A mPAP of > 20 mmHg was noted in 
all subjects, while five of the eight had a mean pulmonary 
arterial pressure of > 40 mmHg (Yotsukura, Miyagawa, 
Tsuya, Ishihara & Ishikawa, 1988).
The majority of CHD in Down syndrome are related to 
septal wall and atrioventricular valve defects (Li et al., 
2012).  From May of 2007 to December of 2008, 704 
patients with congenital heart defects were studied to 
identify independent risk factors of PAH in CHD.  Logistic 
regression analysis revealed that age, systemic artery 
systolic blood pressure, VSD, PDA and combined lesions 
were independent risk factors of PAH in CHD (Li et al., 
2014).  
Discussion
Although there has been significant research in regard to 
DMD, DS and PAH individually, limited study has occurred 
on the correlation between either of the special 
populations and PAH.  Furthermore, it would seem that 
there are no reported studies on the life expectancy or 
quality of life related to early intervention and treatment 
pertaining to individuals with DMD or with DS.  The 
commonality of the pathophysiologic processes involved 
in PAH, regardless of co-morbid conditions, is the 
profound take away.  Evidence-based treatment 
algorithms are available for PAH, centered around the 
functional classification of the patient.
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